Marvin  07241310092D          

  3  2  0  0  0  0            999 V2000
   -0.4125    0.2946    0.0000 Ra  0  0  0  0  0  0  0  0  0  0  0  0
   -1.1270   -0.1179    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.3020   -0.1179    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  1  3  1  0  0  0  0
M  ISO  1   1 223
M  END
> <ID>
CHEBI:74895

> <NAME>
(223)RaCl2

> <DEFINITION>
A radium molecular entity with formula 223RaCl2. Used as as a radiotherapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. An alpha-emitter, radium-223 has a half-life of 11.4 days.

> <STAR>
3

> <SYNONYM>
Radium-223 dichloride

> <IUPAC_NAME>
((223)Ra)radium dichloride

> <BRAND_NAME>
Xofigo

> <FORMULA>
Cl2[223Ra]

> <MASS>
293.920

> <MONOISOTOPIC_MASS>
292.95620

> <CHARGE>
0

> <SMILES>
Cl[223Ra]Cl

> <INCHI>
InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3

> <INCHIKEY>
RWRDJVNMSZYMDV-SIUYXFDKSA-L

> <CAS_REGISTRY_NUMBER>
444811-40-9

> <CHEMIDPLUS>
444811-40-9

> <KEGG_DRUG_ACCESSION>
D10398

> <WIKIPEDIA_ACCESSION>
Radium-223_chloride

> <PUBMED_CITATION>
23682134; 23847352; 23863050

$$$$